Breaking Finance News

A statement released earlier today by Liberum Capital about Shire PLC (LON:SHP) maintains the target price at 5,500.00GBX

Shire PLC (LON:SHP) had its price target hold steady to 5,500GBX by Liberum Capital in a report issued Wednesday August 3 2016. The target price implies a potential upside of 0.08% from the company’s most recent stock close price.

Previously on Tuesday August 2 2016, UBS released a statement for Shire PLC(LON:SHP) raised the target price from 0.00GBX to 5,200.00GBX that suggested an upside of 0.07%.

Just yesterday Shire PLC (LON:SHP) traded 1.73% higher at 5,072.50GBX. The company’s 50-day moving average is 4,955.75GBX and its two hundred day average is 4,434.49GBX. With the last stock close up 16.88% relative to the two hundred day moving average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the same period. 2,204,322 shares of SHP exchanged hands, up from ann average trading volume of 2,149,570.

Performance Graph:


Shire PLC has a price-earnings of 32 with a one-year low of 2,707.19GBX and a one-year high of 5,183.00GBX and has a total market value of 0.0 GBX.

Also covering Shire PLC’s price target, a total of 18 brokers have released a ratings update on SHP. The one year target price is 73.73GBX with six analysts rating the stock a strong buy, 16 analysts rating the company a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and finally 0 analystsrating the stock as sell.

General Information About Shire PLC (LON:SHP)

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), and GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.